drugset / Trial / NCT03744247
Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC
Phase 3
Withdrawn
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University · collabGuangzhou No.12 People's Hospital · collabKaiping Central Hospital · collabThe First Affiliated Hospital of University of South China · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody compared with lenvtinib Alone in patients with advanced hepatocellular carcinoma (HCC)
Timeline
- Start
- 2019-04-21
- Primary completion
- 2021-01-01
- Completion
- 2021-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |